Extrapyramidal plasticity predicts recovery after spinal cord injury

Spinal cord injury (SCI) leads to wide-spread neurodegeneration across the neuroaxis. We explored trajectories of surface morphology, demyelination and iron concentration within the basal ganglia-thalamic circuit over 2 years post-SCI. This allowed us to explore the predictive value of neuroimaging biomarkers and determine their suitability as surrogate markers for interventional trials. Changes in markers of surface morphology, myelin and iron concentration of the basal ganglia and thalamus were estimated from 182 MRI datasets acquired in 17 SCI patients and 21 healthy controls at baseline (1-month post injury for patients), after 3, 6, 12, and 24 months. Using regression models, we investigated group difference in linear and non-linear trajectories of these markers. Baseline quantitative MRI parameters were used to predict 24-month clinical outcome. Surface area contracted in the motor (i.e. lower extremity) and pulvinar thalamus, and striatum; and expanded in the motor thalamus and striatum in patients compared to controls over 2-years. In parallel, myelin-sensitive markers decreased in the thalamus, striatum, and globus pallidus, while iron-sensitive markers decreased within the left caudate. Baseline surface area expansions within the striatum (i.e. motor caudate) predicted better lower extremity motor score at 2-years. Extensive extrapyramidal neurodegenerative and reorganizational changes across the basal ganglia-thalamic circuitry occur early after SCI and progress over time; their magnitude being predictive of functional recovery. These results demonstrate a potential role of extrapyramidal plasticity during functional recovery after SCI

ΔNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation

Background: Delta Np63 alpha is an epithelial progenitor cell marker that maintains epidermal stem cell self-renewal capacity. Previous studies revealed that UV-damage induced p53 phosphorylation is confined to Delta Np63 alpha-positive cells in the basal layer of human epithelium. Results: We now report that phosphorylation of the p53 tumour suppressor is positively regulated by Delta Np63 alpha in immortalised human keratinocytes. Delta Np63 alpha depletion by RNAi reduces steady-state ATM mRNA and protein levels, and attenuates p53 Serine-15 phosphorylation. Conversely, ectopic expression of Delta Np63 alpha in p63-null tumour cells stimulates ATM transcription and p53 Serine-15 phosphorylation. We show that ATM is a direct Delta Np63 alpha transcriptional target and that the Delta Np63 alpha response element localizes to the ATM promoter CCAAT sequence. Structure-function analysis revealed that the Delta Np63-specific TA2 transactivation domain mediates ATM transcription in coordination with the DNA binding and SAM domains. Conclusions: Germline p63 point mutations are associated with a range of ectodermal developmental disorders, and targeted p63 deletion in the skin causes premature ageing. The Delta Np63 alpha-ATM-p53 damage-response pathway may therefore function in epithelial development, carcinogenesis and the ageing processes

A metal-organic framework material that functions as an enantioselective catalyst for olefin epoxidation,” Chem. Commun

A new microporous metal-organic framework compound featuring chiral (salen)Mn struts is highly effective as an asymmetric catalyst for olefin epoxidation, yielding enantiomeric excesses that rival those of the free molecular analogue. Framework confinement of the manganese salen entity enhances catalyst stability, imparts substrate size selectivity, and permits catalyst separation and reuse. Crystalline metal-organic framework (MOF) compounds, especially those exhibiting zeolite-like properties such as high internal surface area and microporosity, comprise a promising emerging class of functional materials. 1 Among the functions most often envisioned is chemical catalysis. 2 The notion is that MOF-based catalysts may be able to replicate some of the key features of zeolitic catalysts (e.g. single-site reactivity, pore-defined substrate size and shape selectivity, easy catalyst separation and recovery, and catalyst recyclability) while incorporating reactivity and properties unique to molecular catalysts. One important property of many molecular catalysts that has yet to be demonstrated with purely zeolitic catalysts is enantioselectivity. Herein, we report that a microporous MOF containing chiral (salen)Mn struts is highly effective as an asymmetric catalyst for olefin epoxidation. The observed enantiomeric excesses (ee) rival those of the free molecular catalyst. At the same time, framework confinement enhances catalyst stability, imparts substrate size selectivity, and permits catalyst separation and reuse. 6 Since MOFs based exclusively upon metal-pyridine bonding tend to collapse if evacuated, L was incorporated instead in a more robust pillared paddlewheel structure, 1, containing pairs of zinc ions together with biphenyldicarboxylate (bpdc) as the second ligand. Notwithstanding the interpenetration, solvent occupies 57% of the volume of 1 as determined by PLATON. Notably, the ligands L of the paired networks are parallel to each other with cyclohexyl and tert-butyl groups protruding along the [100] direction. As such, the channel in the crystallographic b direction is essentially blocked, leaving distorted-rectangular and rhombic channels in the c and a directions with dimensions of 6.2 6 15.7 Å an

Water-stable zirconium-based metal-organic framework material with high-surface area and gas-storage capacities.

We designed, synthesized, and characterized a new Zr-based metal-organic framework material, NU-1100, with a pore volume of 1.53 ccg(-1) and Brunauer-Emmett-Teller (BET) surface area of 4020 m(2) g(-1) ; to our knowledge, currently the highest published for Zr-based MOFs. CH4 /CO2 /H2 adsorption isotherms were obtained over a broad range of pressures and temperatures and are in excellent agreement with the computational predictions. The total hydrogen adsorption at 65 bar and 77 K is 0.092 g g(-1) , which corresponds to 43 g L(-1) . The volumetric and gravimetric methane-storage capacities at 65 bar and 298 K are approximately 180 vSTP /v and 0.27 g g(-1) , respectively.OKF, JTH and RQS thank DOE ARPA-E and the Stanford Global Climate and Energy Project for support of work relevant to methane and CO2, respectively. TY acknowledges support by the U. S. Department of Energy through BES Grant No. DE-FG02-08ER46522. WB acknowledges support from the Foundation for Polish Science through the “Kolumb” Program. DFJ acknowledges the Royal Society (UK) for a University Research Fellowship. This material is based upon work supported by the National Science Foundation (grant CHE-1048773).This is the accepted manuscript. The final version is available as 'Water-Stable Zirconium-Based Metal–Organic Framework Material with High-Surface Area and Gas-Storage Capacities' from Wiley at http://onlinelibrary.wiley.com/doi/10.1002/chem.201402895/abstract

CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity

BACKGROUND: CP-31398 is a small molecule that has been reported to stabilize the DNA-binding core domain of the human tumor suppressor protein p53 in vitro. The compound was also reported to function as a potential anti-cancer drug by rescuing the DNA-binding activity and, consequently, the transcription activation function of mutant p53 protein in mammalian tissue culture cells and in mice. RESULTS: We performed a series of gene expression experiments to test the activity of CP-31398 in yeast and in human cell cultures. With these cell-based assays, we were unable to detect any specific stimulation of mutant p53 activity by this compound. Concentrations of CP-31398 that were reported to be active in the published work were highly toxic to the human H1299 lung carcinoma and Saos-2 cell lines in our experiments. CONCLUSION: In our experiments, the small molecule CP-31398 was unable to reactivate mutant p53 protein. The results of our in vivo experiments are in agreement with the recently published biochemical analysis of CP-31398 showing that this molecule does not bind p53 as previously claimed, but intercalates into DNA

In vivo evidence of remote neural degeneration in the lumbar enlargement after cervical injury

Objective To characterize remote secondary neurodegeneration of spinal tracts and neurons below a cervical spinal cord injury (SCI) and its relation to the severity of injury, the integrity of efferent and afferent pathways, and clinical impairment. Methods A comprehensive high-resolution MRI protocol was acquired in 17 traumatic cervical SCI patients and 14 controls at 3T. At the cervical lesion, a sagittal T2-weighted scan provided information on the width of preserved midsagittal tissue bridges. In the lumbar enlargement, high-resolution T2*-weighted and diffusion-weighted scans were used to calculate tissue-specific cross-sectional areas and diffusion indices, respectively. Regression analyses determined associations between MRI readouts and the electrophysiologic and clinical measures. Results At the cervical injury level, preserved midsagittal tissue bridges were present in the majority of patients. In the lumbar enlargement, neurodegeneration—in terms of macrostructural and microstructural MRI changes—was evident in the white matter and ventral and dorsal horns. Patients with thinner midsagittal tissue bridges had smaller ventral horn area, higher radial diffusivity in the gray matter, smaller motor evoked potential amplitude from the lower extremities, and lower motor score. In addition, smaller width of midsagittal tissue bridges was also associated with smaller tibialis sensory evoked potential amplitude and lower light-touch score. Conclusions This study shows extensive tissue-specific cord pathology in infralesional spinal networks following cervical SCI, its magnitude relating to lesion severity, electrophysiologic integrity, and clinical impairment of the lower extremity. The clinical eloquence of remote neurodegenerative changes speaks to the application of neuroimaging biomarkers in diagnostic workup and planning of clinical trials